OneMedNet Expands Commercial Reach with Atropos Health Partnership

MINNEAPOLIS, Sept. 22, 2026 /CourierPR/ -- OneMedNet Corporation, a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), has expanded its commercial reach through a multi-year agreement with Atropos Health. This strategic partnership will embed OneMedNet's data directly into Atropos Health's evidence-generation platform, providing Atropos customers with access to OneMedNet's multi-modal data.

Under the agreement, Atropos Health will offer its customers the ability to purchase OneMedNet's regulatory decision-grade data through the Atropos platform. The partnership is structured as a three-year subscription-based license, ensuring seamless, ongoing data access and delivery. This collaboration is expected to enhance the quality and depth of evidence generated by Atropos Health, positioning it as a leader in the field.

OneMedNet's data network spans over 2,300 sites and encompasses more than 90 million patient journeys and 270 million studies. This extensive network brings clinical depth that elevates evidence quality beyond what claims or Electronic Health Record (EHR) datasets alone can deliver. The partnership aligns with OneMedNet's strategy of transforming its unique, Direct-from-Source, regulatory decision-grade data into long-term subscription collaborations.

Atropos Health, the creator of real-world evidence for clinical decision-making, sets the standard for rapid, personalized evidence. By adding OneMedNet's regulatory-grade data, the partnership aims to close the evidence gap and provide richer insights for Atropos Health's clients.

The collaboration reflects surging demand for multimodal, regulatory-grade RWD and further validates OneMedNet's focus on converting differentiated data assets into long-term, partnership-driven value. The partnership is structured under a fee arrangement, adding to OneMedNet's Annual Recurring Revenue (ARR). This agreement is expected to strengthen the foundational data beneath Atropos Health's platform workflows, ensuring that customers can move from question to evidence without the usual barriers.

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 90 million patient journeys, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company's platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

This partnership is a significant step for both companies, as it aligns with their shared commitment to delivering high-quality, decision-grade evidence. The collaboration is expected to drive innovation and accelerate the development of new treatments and therapies by providing robust, comprehensive data to researchers and life sciences organizations.